Dr. Sergio Waxman, MD

Dr. Waxman practices at Newark Beth Israel Medical Center in Newark, New Jersey, part of RWJBarnabas Health.

Dr. Waxman's NPI, 1720003494, was assigned on July 13, 2006. Dr. Waxman holds Massachusetts license 74500.

Dr. Waxman's primary practice is Newark Beth Israel Medical Center, at 201 Lyons Ave, Newark, NJ 07112 in Essex County. The practice phone is (973) 926-7000.

Dr. Waxman's primary practice is Newark Beth Israel Medical Center in Newark, New Jersey, part of RWJBarnabas Health. The medical group on file is RWJBarnabas Health Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Waxman practices. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Waxman's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dr. Waxman is licensed in Massachusetts.

CMS data shows 141 Medicare services from Dr. Waxman across 5 procedure codes in 2024, for 87 Medicare patients. Medicare paid $9,680 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 87 Medicare patients who saw Dr. Waxman in 2024. The largest group is 75 to 84, with 32 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 36% are also on Medicaid. Their average risk score is 2.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Waxman's median patient age at 74, with 56% women.

In 2024, Dr. Waxman wrote 91 Medicare Part D claims for 31 patients. 92% of them were for generic drugs. CMS names the drug for 79 of them, across 4 drugs with 11 or more claims each, at $1,093 in total drug cost. In 2018, CMS named 543 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Waxman for performance year 2024, reported through an alternative payment model (APM). Dr. Waxman accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Waxman to 3 clinical trials. Conditions studied include Peripheral Arterial Disease and Peripheral Vascular Diseases. C. R. Bard sponsors the most, 2. Open Payments lists research payments to Dr. Waxman that name 3 trials.

CMS Open Payments shows 640 general payments to Dr. Waxman from 41 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 77% of the total. Boston Scientific Corporation paid the most, $140,096. It also lists 21 research payments totaling $12,952 from 2016 to 2024, naming 3 clinical trials.